Comparison · NCT00702234-sae
Expectant Mothers - Corifollitropin Alfa 150 µg vs Fetuses Present at 10 Weeks After Fresh ET in Base Study: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Expectant Mothers - Corifollitropin Alfa 150 µg vs Fetuses Present at 10 Weeks After Fresh ET in Base Study: serious adverse events. Trial comparisons, record NCT00702234-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00702234-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.541 | 0.481 | 0.6 | wilson | |
| Risk in group 2 | 0.267 | 0.221 | 0.318 | wilson | |
| Risk difference, group 1 minus group 2 | 0.274 | 0.195 | 0.349 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.03 | 1.64 | 2.51 | log | |
| Odds ratio, group 1 over group 2 | 3.24 | 2.29 | 4.58 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Expectant Mothers - Corifollitropin Alfa 150 µg than on Fetuses Present at 10 Weeks After Fresh ET in Base Study | 3.64 | 2.87 | 5.12 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Expectant Mothers - Corifollitropin Alfa 150 µg | In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following treatments: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of (rec)hCG (5,000-10,000 IU/250 µg). Daily dosing with FSH (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh ET in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered. | 145 | 268 | EG000 |
| Group 2 | Fetuses Present at 10 Weeks After Fresh ET in Base Study | This group includes fetuses associated with expectant mothers who were administered corifollitropin alfa in base study P05714 (NCT00696878) who were enrolled in this follow-up study P05715. The fetuses were present at 10 weeks after fresh ET in base study P05714 and/or at enrollment of the expectant mother in this follow-up study P05715. | 84 | 315 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From approximately 10 weeks after fresh ET in base study P05714 (NCT00696878) up to 12 weeks after birth in current follow-up study (Up to approximately 9 months).
Source ClinicalTrials.gov
Trial
- Title
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)
- NCT number
- NCT00702234
- Phases
- Conditions
- Pregnancy, Neonates
- Interventions
- Corifollitropin alfa, GnRH antagonist, (rec)hCG, FSH, Progesterone
- Lead sponsor
- Organon and Co
- Results first posted
- 2015-04-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00702234?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00702234-sae